Patent Grant
11185662
Successful treatment of hypertension is important for many reasons. For example, successful treatment of hypertension has significant clinical benefits in preventing or limiting conditions caused by or exacerbated by hypertension, such as renal disease, arrhythmias, and congestive heart failure, to name a few. While drug therapy can be used to treat hypertension, it is not always successful. Some people are resistant to drug therapy treatment or experience significant side effects from drug therapy treatment.
Hypertension can be treated by inactivating conduction of the renal nerves surrounding the renal artery. Sympathetic renal nerve activity plays a significant role in the initiation and maintenance of hypertension. When the brain perceives increased renal nerve activity, signaling low blood volume or a drop in blood pressure, it compensates by increasing sympathetic nerve activity to the heart, the liver, and the kidneys, which results in increased cardiac output; insulin resistance; and most importantly, increased renin production by the kidneys. Renin stimulates the production of angiotensin, which causes blood vessels to constrict, resulting in increased blood pressure and stimulates the secretion of aldosterone. Aldosterone causes the kidneys to increase the reabsorption of sodium and water into the blood, increasing blood volume thereby further increasing blood pressure.
It has been established for years that surgically cutting renal nerves results in a decrease in blood pressure and water retention to normal levels; thereby allowing the patients' heart, liver, and kidneys to also return to healthier functioning. It has also been shown a disruption of the renal nerves has no serious ill effects. However, surgically cutting the renal nerves requires a major surgical procedure with risks of undesirable side effects. It would be desirable to produce the same result without major surgery.
In order to explain the difficulties associated with accomplishing this task without causing other damage, the anatomy of the renal arteries and nerves will be described now. Shown in
The inability to locate and target the renal nerves 8 makes it difficult to disconnect the sympathetic renal activity using non-surgical techniques without causing damage to the renal artery 10 or causing other side effects. For example, attempts to apply energy to the renal nerves can cause effects such as stenosis, intimal hyperplasia, and necrosis. Other side effects can include thrombosis, platelet aggregation, fibrin clots and vasoconstriction. In addition, the inability to target and locate the renal nerves 8 makes it difficult to ensure that sympathetic renal nerve activity has been discontinued enough to achieve an acceptable therapeutic treatment.
U.S. Pat. No. 7,617,005 suggests the use of a radio frequency (“RF”) emitter connected to a catheter, which is inserted in the renal artery. The RF emitter is placed against the intima and the RF energy is emitted to heat the renal nerves to a temperature that reduces the activity of renal nerves which happen to lie in the immediate vicinity of the emitter. In order to treat all the renal nerves surrounding the renal arteries, the RF emitter source must be repositioned around the inside of each renal artery multiple times. The emitter may miss some of the renal nerves, leading to an incomplete treatment. Moreover, the RF energy source must contact the intima to be able to heat the renal nerves, which may cause damage or necrosis to the single layer endothelium and the intima, potentially causing intimal hyperplasia, renal artery stenosis, and renal artery dissection.
The '005 Patent also suggests the use of high-intensity focused ultrasound to deactivate the renal nerves. The described high-intensity focused ultrasound energy source assertedly emits ultrasound energy in a 360° pattern around the axis of the renal artery, and does not need to contact the intima 3. However, the high-intensity focused ultrasound source applies concentrated energy in a thin focal ring surrounding the artery. It is difficult or impossible to align this thin ring with the renal nerves because it is difficult or impossible to visualize and target the renal nerves with current technology, and because the renal nerves may lie at different radial distances from the central axis of the renal artery. The latter problem is aggravated in patients who have renal arteries with large variations in shape or thickness. Moreover, the thin focal ring can encompass only a small segment of each renal nerve along the lengthwise direction of the nerves and artery. Since nerves tend to re-grow, a small treatment zone allows the nerves to reconnect in a shorter period of time.
For many years ultrasound has been used to enhance cell repair, stimulate the growth of bone cells, enhance delivery of drugs to specific tissues, and to image tissue within the body. In addition, high-intensity focused ultrasound has been used to heat and ablate tumors and tissue within the body. Ablation of tissue has been performed nearly exclusively by high-intensity focused ultrasound because the emitted ultrasound energy is focused on a specific location to allow precise in-depth tissue necrosis without affecting surrounding tissue and intervening structures that the ultrasound energy must pass through.
U.S. Pat. No. 6,117,101, to Diederich, discusses use of highly collimated ultrasound energy rather than high intensity focused ultrasound for ablating tissue to create a scar ring within the pulmonary vein for blocking the conduction of electrical signals to the heart.
U.S. Patent Publication No. 20100179424 (application Ser. No. 12/684,067), the disclosure of which is incorporated by reference herein, uses unfocused ultrasound for the treatment of mitral valve regurgitation. In the '474 Publication, unfocused ultrasound energy is used to heat and shrink the collagen associated with the mitral annulus. This apparatus uses an inflatable balloon in order to place the ultrasound transducer into the correct location, thereby targeting the mitral annulus. In this apparatus, a part of the balloon contacts the tissue to be heated.
One aspect of the invention provides apparatus for inactivating renal nerve conduction in a human or non-human mammalian subject. The apparatus according to this aspect of the invention preferably includes an ultrasound transducer adapted for insertion into a renal artery of the mammalian subject. The ultrasound transducer desirably is arranged to transmit unfocused ultrasound energy. The apparatus according to this aspect of the invention desirably also includes an actuator electrically connected to the transducer. The actuator most preferably is adapted to control the ultrasound transducer to transmit unfocused ultrasound energy into an impact volume of at least approximately 0.5 cm3, encompassing the renal artery so that the unfocused ultrasound energy is applied at a therapeutic level sufficient to inactivate conduction of renal nerves throughout the impact volume. As discussed further below, such therapeutic level is below the level required for tissue ablation.
The apparatus may further include a catheter with a distal end and a proximal end, the transducer being mounted to the catheter adjacent the distal end, the catheter and transducer being constructed and arranged to allow a substantial flow of blood through the renal artery while the ultrasound transducer is positioned within the renal artery. The catheter may be constructed and arranged to hold the transducer out of contact with the wall of the renal artery. The catheter may have an expansible element such as a balloon, wire basket or the like mounted adjacent the distal end. For example, the transducer may be adapted to transmit the ultrasound energy in a 360° cylindrical pattern surrounding a transducer axis, and the catheter may be constructed and arranged to hold the axis of the transducer generally parallel to the axis of the renal artery.
A further aspect of the invention provides methods for inactivating renal nerve conduction in a mammalian subject. A method according to this aspect of the invention desirably includes the steps of inserting an ultrasound transducer into a renal artery of the subject and actuating the transducer to transmit therapeutically effective unfocused ultrasound energy into an impact volume of at least approximately 0.5 cm3 encompassing the renal artery. The ultrasound energy desirably is applied so that the therapeutically effective unfocused ultrasound energy inactivates conduction of all the renal nerves in the impact volume. For example, the step of actuating the transducer may be so as to maintain the temperature of the renal artery wall below 65° C. while heating the solid tissues within the impact volume, including the renal nerves in the impact volume, to above 42° C.
Because the impact volume is relatively large, and because the tissues throughout the impact volume preferably reach temperatures sufficient to inactivate nerve conduction, the preferred methods according to this aspect of the invention can be performed successfully without determining the actual locations of the renal nerves, and without targeting or focusing on the renal nerves. The treatment can be performed without measuring the temperature of tissues. Moreover, the treatment preferably is performed without causing stenosis of the renal artery, intimal hyperplasia, or other injuries that would require intervention. The preferred methods and apparatus can inactive relatively long segments of the renal nerves, so as to reduce the possibility of nerve recovery which would re-establish conduction along the inactivated segments.
Further aspects of the invention provide probes which can be used in the method and apparatus discussed above, and apparatus incorporating means for performing the steps of the methods discussed above.
Apparatus according to one embodiment of the invention (
The apparatus also includes a catheter 18 having a proximal end 20, a distal end 22 and a proximal-to-distal axis which, in the condition depicted in
The distal end 22 of the catheter 18 is preformed so that when the distal end of the catheter is outside of the sheath 12, the distal end tends to assume a hooked configuration as indicated in broken lines at 22′ in
Catheter 18 has a balloon 24 mounted at the distal end 22. In its inflated condition (
An ultrasound transducer 30 (
Transducer 30 is arranged so that ultrasonic energy generated in the transducer is emitted principally from the exterior emitting surface. Thus, the transducer may include features arranged to reflect ultrasonic energy directed toward the interior of the transducer so that the reflected energy reinforces the ultrasonic vibrations at the exterior surface. For example, support tube 84 and transducer 30 may be configured so that the interior surface of the transducer 30 is spaced apart from the exterior surface of the support tube, which is formed from metal, by a gap (not shown). The distance across the gap, between the interior surface of the transducer and the exterior surface of the support tube may be one half the wavelength of the ultrasound energy emitted by the transducer, to promote efficient operation of the transducer 30. In this embodiment, the ultrasound energy generated by the transducer 30 is reflected at the water gap to reinforce ultrasound energy propagating from the transducer 30, thereby ensuring the ultrasound energy is directed outwardly from an external surface of the transducer 30.
Transducer 30 is also arranged to convert ultrasonic waves impinging on the exterior surface 31 into electrical signals on wires 32. Stated another way, transducer 30 can act either as an ultrasonic emitter or an ultrasonic receiver.
The transducer 30 is designed to operate, for example, at a frequency of approximately 1 MHz to approximately a few tens of MHz, and typically at approximately 9 MHz. The actual frequency of the transducer 30 typically varies somewhat depending on manufacturing tolerances. The optimum actuation frequency of the transducer may be encoded in a machine-readable or human-readable element (not shown) such as a digital memory, bar code or the like affixed to the catheter. Alternatively, the readable element may encode a serial number or other information identifying the individual catheter, so that the optimum actuation frequency may be retrieved from a central database accessible through a communication link such as the internet.
An ultrasound system 20, also referred to herein as an actuator, is releasably connected to catheter 18 and transducer 30 through a plug connector 88 (
The circulation device 48 is connected to lumens (not shown) within catheter 18 which in turn are connected to balloon 24. The circulation device is arranged to circulate a liquid, preferably an aqueous liquid, through the catheter 18 to the transducer 30 in the balloon 24. The circulation device 48 may include elements such as a tank for holding the circulating coolant 35, pumps 37, a refrigerating coil (not shown), or the like for providing a supply of liquid to the interior space of the balloon 24 at a controlled temperature, desirably at or below body temperature. The control board 42 interfaces with the circulation device 48 to control the flow of fluid into and out of the balloon 24. For example, the control board 42 may include motor control devices linked to drive motors associated with pumps for controlling the speed of operation of the pumps 37. Such motor control devices can be used, for example, where the pumps 37 are positive displacement pumps, such as peristaltic pumps. Alternatively or additionally, the control circuit may include structures such as controllable valves connected in the fluid circuit for varying resistance of the circuit to fluid flow (not shown). The ultrasound system 20 may further include two pressure sensors 38, to monitor the liquid flow through the catheter 18. One pressure sensor monitors the flow of the liquid to the distal catheter 18 to determine if there is a blockage while the other monitors leaks in the catheter 18. While the balloon is in an inflated state, the pressure sensors 38 maintain a desired pressure in the balloon preferably at approximately 3 pounds per square inch (20 KPa).
The ultrasound system 20 incorporates a reader 46 for reading a machine-readable element on catheter 18 and conveying the information from such element to control board 46. As discussed above, the machine-readable element on the catheter may include information such as the operating frequency of the transducer 30 in a particular catheter 18, and the control board 42 may use this information to set the appropriate frequency for exciting the transducer. Alternatively, the control board may be arranged to actuate excitation source 44 to measure the transducer operating frequency by energizing the transducer at a low power level while scanning the excitation frequency over a pre-determined range of frequencies for example 8.5 Mhz-9.5 Mhz, and monitoring the response of the transducer to such excitation.
The ultrasonic system 20 may be similar to that disclosed in U.S. Provisional Patent Application No. 61/256,002, filed Oct. 29, 2009, entitled “METHOD AND APPARATUS FOR PERCUTANEOUS TREATMENT OF MITRAL VALVE REGURGITATION (PMVR),” the disclosure of which is incorporated by reference herein.
A method according to an embodiment of the present invention is depicted in flowchart form in
Once the distal end of the catheter is in position within a renal artery, pumps 37 bring balloon 24 to an inflated condition as depicted in
In the next step 58, the ultrasound system 20 uses transducer 30 to measure the size of the renal artery 10. Control board 42 and ultrasound source 44 actuate the transducer 30 to “ping” the renal artery 10 with a low-power ultrasound pulse. The ultrasonic waves in this pulse are reflected by the artery wall onto transducer 30 as echoes. Transducer 30 converts the echoes to echo signals on wires 32. The ultrasound system 20 then determines the size of the artery 10 by analyzing the echo signals. For example, the ultrasound system 20 may determine the time delay between actuation of the transducer to produce the “ping” and the return of echo signals. In step 60, the ultrasound system 20 uses the measured artery size to set the acoustic power to be delivered by transducer 30 during application of therapeutic ultrasonic energy in later steps. For example, control board 42 may use a lookup table correlating a particular echo delay (and thus artery diameter) with a particular power level. Generally, the larger the artery diameter, the more power should be used. Variations in the shape of the renal artery 10, or in the centering of the transducer 30, may cause a range of time delay in the echo signals. The ultrasound system 20 may take an average of the range to determine the average size of the renal artery 10 and make adjustments to the power level based on the average size.
The physician then initiates the treatment (step 60) through the user interface 40. In the treatment (step 64), the ultrasonic system or actuator 20, and particularly the control board 42 and ultrasonic source 44, actuate transducer 30 to deliver therapeutically effective ultrasonic waves to an impact volume 11 (
The selected operating frequency, unfocused characteristic, placement, size, and the shape of the ultrasound transducer 30 allows the entire renal artery 10 and renal nerves to lie within the “near field” region of the transducer 30. Within this region, an outwardly spreading, unfocused omni-directional (360°) cylindrical beam of ultrasound waves generated by the transducer 30 tends to remain collimated and has an axial length approximately equal to the axial length of the transducer 30. For a cylindrical transducer, the radial extent of the near field region is defined by the expression L2/λ, where L is the axial length of the transducer 30 and λ is the wavelength of the ultrasound waves. At distances from the transducer 30 surface greater than L2/λ, the beam begins to spread axially to a substantial extent. However, for distances less than L2/λ, the beam does not spread axially to any substantial extent. Therefore, within the near field region, at distances less than L2/λ, the intensity of the ultrasound energy decreases linearly, in proportion to distance from the transducer 30 surface, as the unfocused beam spreads radially. As used in this disclosure, the term “unfocused” refers to a beam, which does not increase in intensity in the direction of propagation of the beam away from the transducer 30.
The impact volume 11 is generally cylindrical and coaxial with the renal artery. It extends from the transducer surface to an impact radius 39, where the intensity of the ultrasonic energy is too small to heat the tissue to the temperature range that will cause inactivation of the renal nerves 8. The impact radius 39 is determined by the dosage of ultrasound energy transmitted from the transducer 30. The volume V of impact volume 11 is determined by the following equation:
V=πr22h−πr12h
where
As discussed above, the length of the transducer 30 may vary between 2 mm and 10 mm, but is preferably 6 mm to provide a wide inactivation zone of the renal nerves. The diameter of the transducer 30 may vary between 1.5 mm to 3.0 mm, and is preferably 2.0 mm. The dosage is selected not only for its therapeutic effect, but also to allow the radius 39 of the impact volume 11 to be between preferably 5 mm to 7 mm in order to encompass the renal artery 10, and adjacent renal nerves, all of which lie within an average radius of 3-4 mm, without transmitting damaging ultrasound energy to structures beyond the renal artery 10. This will result in an impact volume 11 of at least 0.5 cm3, with the length of renal nerve inactivation closely corresponding to the length of the transducer 32.
The power level desirably is selected so that throughout the impact volume, solid tissues are heated to about 42° C. or more for at several seconds or more, but desirably all of the solid tissues, including the intima of the renal artery remain well below 65° C. Thus, throughout the impact region, the solid tissues (including all of the renal nerves) are brought to a temperature sufficient to inactivate nerve conduction but below that which causes rapid necrosis of the tissues.
Research shows that nerve damage occurs at much lower temperatures and much faster than tissue necrosis. See Bunch, Jared. T. et al. “Mechanisms of Phrenic Nerve Injury During Radiofrequency Ablation at the Pulmonary Vein Orifice, Journal of Cardiovascular Electrophysiology, Volume 16, Issue 12, pg. 1318-1325 (Dec. 8, 2005), incorporated by reference herein. Since, necrosis of tissue typically occurs at temperatures of 65° C. or higher for approximately 10 sec or longer while inactivation of the renal nerves 8 typically occurs when the renal nerves 8 are at temperatures of 42° C. or higher for several seconds or longer, the dosage of the ultrasound energy is chosen to keep the temperature in the impact volume 11 between those temperatures for several seconds or longer. The dosage of ultrasonic energy desirably is also less than that required to cause substantial shrinkage of collagen in the impact volume. Operation of the transducer thus provides a therapeutic dosage, which inactivates the renal nerves 8 without causing damage to the renal artery 10, such as, stenosis, intimal hyperplasia, intimal necrosis, or other injuries that would require intervention. The continued flow of blood across the inside wall of the renal artery 10 ensures the intimal layer 3 (
In order to generate the therapeutic dosage of ultrasound energy, the acoustic power output of the transducer typically is approximately 10 watts to approximately 100 watts, more typically approximately 20 to approximately 30 watts. The duration of power application typically is approximately 2 seconds to approximately a minute or more, more typically approximately 10 seconds to approximately 20 seconds. The optimum dosage used with a particular system to achieve the desired temperature levels may be determined by mathematical modeling or animal testing.
The impact volume 11 of the unfocused ultrasound energy encompasses the entire renal artery 10, including the adventitia and closely surrounding tissues, and hence encompasses all of the renal nerves surrounding the renal artery. Therefore, the placement in the renal artery 10 of the transducer 30 may be indiscriminate in order to inactivate conduction of all the renal nerves 8 surrounding the renal arteries 10 in the subject. As used in this disclosure “indiscriminate” and “indiscriminately” mean without targeting, locating, or focusing on any specific renal nerves.
Optionally, the physician may then reposition the catheter 18 and transducer 30 along the renal artery (step 66) and reinitiate the treatment 68 to retransmit therapeutically effective unfocused ultrasound energy (step 70). This inactivates the renal nerves at an additional location along the length of the renal artery, and thus provides a safer and more reliable treatment. The repositioning and retransmission steps optionally can be performed multiple times. Next the physician moves the catheter 18 with the transducer 30 to the other renal artery 10 and performs the entire treatment again for that artery 10, (step 72). After completion of the treatment, the catheter 18 is withdrawn from the subject's body (step 74).
Numerous variations and combinations of the features discussed above can be utilized. For example, the ultrasound system 20 may control the transducer 30 to transmit ultrasound energy in a pulsed function during application of therapeutic ultrasonic energy. The pulsed function causes the ultrasound transducer 30 to emit the ultrasound energy at a duty cycle of, for example, 50%. Pulse modulation of the ultrasound energy is helpful in limiting the tissue temperature while increasing treatment times.
In a further variant, the steps of measuring the renal artery size and adjusting the dose (steps 58 and 72) may be omitted. In this instance, the transducer is simply operated at a preset power level sufficient for the renal arteries of an average subject. In a further variant, the renal artery diameter can be measured by techniques other than actuation of transducer 30 as, for example, by radiographic imaging using a contrast agent introduced into the renal artery or magnetic resonance imaging or use of a separate ultrasonic measuring catheter. In this instance, the data from the separate measurement can be used to set the dose.
In the particular embodiment discussed above, the transducer 30 is centered in the renal artery by the non-circular element 80 of expansible balloon 24. Other centering arrangements can be used. For example, an expansible balloon encompassing the transducer may be a balloon of circular cross-section slightly smaller in diameter than the renal artery 10. Such a balloon allows blood to continue to flow through the renal artery 10, but maintains the transducer 30 roughly centered in the renal artery 10. In this embodiment, the balloon 24 is dynamic rather than fitted to the renal artery 10 because the flow of blood around the balloon 24 causes small back and forth movements. This dynamic nature allows the blood to continue to reach all parts of the renal artery 10, thereby providing cooling and minimizing damage to the intima 3. In other embodiments, the distal end of the catheter can include expansible structures other than balloons, such as a wire basket or wire mesh structure which can be selectively brought to a radially expanded condition, such as by compressing the structure in the axial direction. The wire basket may be non-reflecting to ultrasound, or may be mounted on the catheter at a position axially offset from the transducer 30.
In a further variant, the balloon 24 may be formed from a porous membrane or include holes, such that cooled liquid being circulated within the balloon 24 may escape or be ejected from the balloon 24 into the blood stream within the renal artery 10. The escaping or ejected cooled liquid from the balloon 24 that enters the blood flow may support further cooling of the inner lining of the renal artery 10, which is in contact with the flowing blood.
Typically, catheter 18 is a disposable, single-use device. The catheter 18 or ultrasonic system 20 may contain a safety device that inhibits the reuse of the catheter 18 after a single use. Such safety devices per se are known in the art.
In yet another variant, the catheter 18 itself may include a steering mechanism which allows the physician to directly steer the distal end 22 of the catheter. The sheath may be omitted.
Another variation may be that an energy emitter unit at the distal end of the catheter 18, which includes the ultrasound transducer 30, may be positioned in the renal vein, and the ultrasound transducer 30 may include reflective or blocking structures for selectively directing ultrasound energy from the transducer 30 over only a limited range of radial directions to provide that ultrasound energy desirably is selectively directed from the transducer 30 in the renal vein toward the renal artery 10. When the venous approach is utilized, the ultrasound energy is directed into a segment or beam propagating away from an exterior surface of the transducer 30, commonly known as a side firing transducer 30 arrangement. For example, the ultrasound transducer 30 may have a construction and be operated to emit directed ultrasound energy 5 similarly as disclosed in U.S. Provisional Application No. 61/256,002, filed Oct. 29, 2009, entitled “METHOD AND APPARATUS FOR PERCUTANEOUS TREATMENT OF MITRAL VALVE REGURGITATION (PMVR),” incorporated by reference herein. In this variation, the route by which the catheter 18 is introduced into the body, and then positioned close to the kidneys 6, is varied from the atrial approach discussed above. A venous approach may be utilized to take advantage of the potential for reduced closure issues after catheter 18 withdrawal.
Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.
This application is a continuation of U.S. patent application Ser. No. 13/826,645, filed Mar. 14, 2013, now U.S. Pat. No. 10,039,901, which is a continuation of U.S. patent application Ser. No. 13/503,109, filed May 30, 2012, now U.S. Pat. No. 9,981,108, which is a national phase of International PCT Patent Application Serial No. PCT/US10/54637, filed Oct. 29, 2010, which claims the benefit of U.S. Provisional Patent Application Nos. 61/256,429, filed Oct. 30, 2009 and 61/292,618, filed Jan. 6, 2010, the entire contents of each of which are incorporated by reference herein. The present application is also related to U.S. patent application Ser. No. 14/731,347, filed Jun. 4, 2015, now U.S. Pat. No. 9,943,666.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3938502 | Bom | Feb 1976 | A |
| 4802490 | Johnston | Feb 1989 | A |
| 4841977 | Griffith et al. | Jun 1989 | A |
| 5295992 | Cameron | Mar 1994 | A |
| 5295995 | Kleiman | Mar 1994 | A |
| 5308356 | Blackshear et al. | May 1994 | A |
| 5324255 | Passafaro et al. | Jun 1994 | A |
| 5327885 | Griffith | Jul 1994 | A |
| 5354200 | Klein et al. | Oct 1994 | A |
| 5354220 | Ganguly et al. | Oct 1994 | A |
| 5400267 | Denen et al. | Mar 1995 | A |
| 5423220 | Finsterwald et al. | Jun 1995 | A |
| 5456259 | Barlow et al. | Oct 1995 | A |
| 5524491 | Cavalloni | Jun 1996 | A |
| 5620479 | Diederich | Apr 1997 | A |
| 5630837 | Crowley | May 1997 | A |
| 5713849 | Bosma et al. | Feb 1998 | A |
| 5769812 | Stevens et al. | Jun 1998 | A |
| 5775338 | Hastings | Jul 1998 | A |
| 5803083 | Buck et al. | Sep 1998 | A |
| 5938645 | Gordon | Aug 1999 | A |
| 6097985 | Kasevich et al. | Aug 2000 | A |
| 6102863 | Pflugrath et al. | Aug 2000 | A |
| 6117101 | Diederich et al. | Sep 2000 | A |
| 6128522 | Acker et al. | Oct 2000 | A |
| 6149596 | Bancroft | Nov 2000 | A |
| 6190377 | Kuzdrall | Feb 2001 | B1 |
| 6216704 | Ingle et al. | Apr 2001 | B1 |
| 6277077 | Brisken et al. | Aug 2001 | B1 |
| 6299583 | Eggers et al. | Oct 2001 | B1 |
| 6355030 | Aldrich et al. | Mar 2002 | B1 |
| 6475146 | Frelburger et al. | Nov 2002 | B1 |
| 6492762 | Pant et al. | Dec 2002 | B1 |
| 6517534 | McGovern et al. | Feb 2003 | B1 |
| 6547788 | Maguire | Apr 2003 | B1 |
| 6599256 | Acker et al. | Jul 2003 | B1 |
| 6599288 | Maguire et al. | Jul 2003 | B2 |
| 6607502 | Maguire et al. | Aug 2003 | B1 |
| 6635054 | Fjield et al. | Oct 2003 | B2 |
| 6645202 | Pless et al. | Nov 2003 | B1 |
| 6712767 | Hossack et al. | Mar 2004 | B2 |
| 6763722 | Fjield et al. | Jul 2004 | B2 |
| 6793635 | Ryan et al. | Sep 2004 | B2 |
| 6913581 | Corl et al. | Jul 2005 | B2 |
| 6953469 | Ryan | Oct 2005 | B2 |
| 6978174 | Gelfand et al. | Dec 2005 | B2 |
| 7162303 | Levin et al. | Jan 2007 | B2 |
| 7285116 | de la Rama et al. | Oct 2007 | B2 |
| 7297413 | Mitsumori | Nov 2007 | B2 |
| 7347852 | Hobbs et al. | Mar 2008 | B2 |
| 7473224 | Makin | Jan 2009 | B2 |
| 7540846 | Harhen et al. | Jun 2009 | B2 |
| 7617005 | Demarais et al. | Nov 2009 | B2 |
| 7620451 | Demarais et al. | Nov 2009 | B2 |
| 7625371 | Morris et al. | Dec 2009 | B2 |
| 7647115 | Levin et al. | Jan 2010 | B2 |
| 7653438 | Deem | Jan 2010 | B2 |
| 7678104 | Keidar | Mar 2010 | B2 |
| 7717948 | Demarais et al. | May 2010 | B2 |
| 7756583 | Demarais | Jul 2010 | B2 |
| 7837676 | Sinelnikov et al. | Nov 2010 | B2 |
| 7846317 | Meltzer et al. | Dec 2010 | B2 |
| 7873417 | Demarais et al. | Jan 2011 | B2 |
| 7937143 | Demarais et al. | May 2011 | B2 |
| 8131371 | Demarals et al. | Mar 2012 | B2 |
| 8233221 | Suijver et al. | Jul 2012 | B2 |
| 8251986 | Chornenky et al. | Aug 2012 | B2 |
| 8287472 | Ostrovsky et al. | Oct 2012 | B2 |
| 8475442 | Hall et al. | Jul 2013 | B2 |
| 8485993 | Orszulak et al. | Jul 2013 | B2 |
| 8504147 | Deem et al. | Aug 2013 | B2 |
| D697036 | Kay et al. | Jan 2014 | S |
| 8715209 | Gertner | May 2014 | B2 |
| 8734438 | Behnke | May 2014 | B2 |
| D708810 | Lewis, Jr. | Jul 2014 | S |
| 8808345 | Clark et al. | Aug 2014 | B2 |
| D712352 | George et al. | Sep 2014 | S |
| D712353 | George et al. | Sep 2014 | S |
| D712833 | George et al. | Sep 2014 | S |
| 8974445 | Warnking et al. | Mar 2015 | B2 |
| 9675413 | Deem et al. | Jun 2017 | B2 |
| 9700372 | Schaer | Jul 2017 | B2 |
| 9707034 | Schaer | Jul 2017 | B2 |
| 9943666 | Warnking | Apr 2018 | B2 |
| 9981108 | Warnking | May 2018 | B2 |
| 10039901 | Warnking | Aug 2018 | B2 |
| 20010007940 | Tu et al. | Jul 2001 | A1 |
| 20020002334 | Okuno et al. | Jan 2002 | A1 |
| 20020002371 | Acker et al. | Jan 2002 | A1 |
| 20020022833 | Maguire et al. | Feb 2002 | A1 |
| 20020065512 | Fjield et al. | May 2002 | A1 |
| 20020087156 | Maguire et al. | Jul 2002 | A1 |
| 20020150693 | Kobayashi et al. | Oct 2002 | A1 |
| 20020151889 | Swanson et al. | Oct 2002 | A1 |
| 20020156469 | Yon et al. | Oct 2002 | A1 |
| 20020165535 | Lesh et al. | Nov 2002 | A1 |
| 20020193781 | Loeb | Dec 2002 | A1 |
| 20030060813 | Loeb et al. | Mar 2003 | A1 |
| 20030125726 | Maguire et al. | Jul 2003 | A1 |
| 20030138571 | Kunishi et al. | Jul 2003 | A1 |
| 20030181963 | Pellegrino et al. | Sep 2003 | A1 |
| 20030204138 | Choi | Oct 2003 | A1 |
| 20030216721 | Diederich et al. | Nov 2003 | A1 |
| 20030216792 | Levin et al. | Nov 2003 | A1 |
| 20030216794 | Becker et al. | Nov 2003 | A1 |
| 20030225331 | Diederich et al. | Dec 2003 | A1 |
| 20030233099 | Danaek et al. | Dec 2003 | A1 |
| 20040044286 | Hossack et al. | Mar 2004 | A1 |
| 20040082859 | Schaer | Apr 2004 | A1 |
| 20040167415 | Gelfand et al. | Aug 2004 | A1 |
| 20040230116 | Cowan et al. | Nov 2004 | A1 |
| 20040253450 | Seita et al. | Dec 2004 | A1 |
| 20050009218 | Kunihiro | Jan 2005 | A1 |
| 20050035901 | Lyon | Feb 2005 | A1 |
| 20050215990 | Govari | Sep 2005 | A1 |
| 20050234523 | Levin et al. | Oct 2005 | A1 |
| 20050256518 | Rama et al. | Nov 2005 | A1 |
| 20050288730 | Deem | Dec 2005 | A1 |
| 20060041277 | Deem et al. | Feb 2006 | A1 |
| 20060058711 | Harhen | Mar 2006 | A1 |
| 20060064081 | Rosinko | Mar 2006 | A1 |
| 20060088705 | Mitsumori | Apr 2006 | A1 |
| 20060100514 | Lopath | May 2006 | A1 |
| 20060121200 | Halpert et al. | Jun 2006 | A1 |
| 20060154072 | Schlossman et al. | Jul 2006 | A1 |
| 20060155269 | Warnking | Jul 2006 | A1 |
| 20060184072 | Manna | Aug 2006 | A1 |
| 20060212076 | Demarais et al. | Sep 2006 | A1 |
| 20060212078 | Demarais et al. | Sep 2006 | A1 |
| 20060229594 | Francischelli et al. | Oct 2006 | A1 |
| 20060241523 | Sinelnikov et al. | Oct 2006 | A1 |
| 20060265014 | Demarais et al. | Nov 2006 | A1 |
| 20060265015 | Demarais | Nov 2006 | A1 |
| 20060270976 | Savage et al. | Nov 2006 | A1 |
| 20060276852 | Demarais et al. | Dec 2006 | A1 |
| 20070124458 | Kumar | May 2007 | A1 |
| 20070129720 | Demarais | Jun 2007 | A1 |
| 20070129760 | Demarais et al. | Jun 2007 | A1 |
| 20070135875 | Demarais | Jun 2007 | A1 |
| 20070173899 | Levin et al. | Jul 2007 | A1 |
| 20070175359 | Hwang | Aug 2007 | A1 |
| 20070203547 | Costello et al. | Aug 2007 | A1 |
| 20070203549 | Demarais | Aug 2007 | A1 |
| 20070255267 | Diederich et al. | Nov 2007 | A1 |
| 20070255342 | Laufer | Nov 2007 | A1 |
| 20070265609 | Thapliyal et al. | Nov 2007 | A1 |
| 20070265610 | Thapliyal et al. | Nov 2007 | A1 |
| 20070265687 | Deem et al. | Nov 2007 | A1 |
| 20070282407 | Demarais et al. | Dec 2007 | A1 |
| 20070293762 | Sawada et al. | Dec 2007 | A1 |
| 20080052186 | Walker et al. | Feb 2008 | A1 |
| 20080151001 | Sudo et al. | Jun 2008 | A1 |
| 20080252172 | Yetter et al. | Oct 2008 | A1 |
| 20080255449 | Warnking et al. | Oct 2008 | A1 |
| 20080255478 | Burdette | Oct 2008 | A1 |
| 20080255642 | Zarins et al. | Oct 2008 | A1 |
| 20090024195 | Rezai et al. | Jan 2009 | A1 |
| 20090036948 | Levin et al. | Feb 2009 | A1 |
| 20090062873 | Wu et al. | Mar 2009 | A1 |
| 20090076409 | Wu et al. | Mar 2009 | A1 |
| 20090118125 | Kobayashi et al. | May 2009 | A1 |
| 20090118725 | Auth et al. | May 2009 | A1 |
| 20090124964 | Leach et al. | May 2009 | A1 |
| 20090149753 | Govari et al. | Jun 2009 | A1 |
| 20090171202 | Kirkpatrick et al. | Jul 2009 | A1 |
| 20090189485 | Iyoki | Jul 2009 | A1 |
| 20090204006 | Wakabayashi et al. | Aug 2009 | A1 |
| 20090221939 | Demarais et al. | Sep 2009 | A1 |
| 20090228003 | Sinelnikov | Sep 2009 | A1 |
| 20090248011 | Hlavka et al. | Oct 2009 | A1 |
| 20090299360 | Ormsby | Dec 2009 | A1 |
| 20090312673 | Thapliyal et al. | Dec 2009 | A1 |
| 20090312693 | Thapliyal et al. | Dec 2009 | A1 |
| 20090312755 | Thapliyal et al. | Dec 2009 | A1 |
| 20100016762 | Thapliyal et al. | Jan 2010 | A1 |
| 20100033940 | Yamaguchi et al. | Feb 2010 | A1 |
| 20100049099 | Thapliyal et al. | Feb 2010 | A1 |
| 20100113928 | Thapliyal et al. | May 2010 | A1 |
| 20100113985 | Thapliyal et al. | May 2010 | A1 |
| 20100114094 | Thapliyal et al. | May 2010 | A1 |
| 20100125198 | Thapliyal et al. | May 2010 | A1 |
| 20100130892 | Warnking | May 2010 | A1 |
| 20100137860 | Demarais et al. | Jun 2010 | A1 |
| 20100137952 | Demarais et al. | Jun 2010 | A1 |
| 20100152582 | Thapliyal et al. | Jun 2010 | A1 |
| 20100168731 | Wu et al. | Jul 2010 | A1 |
| 20100168737 | Grunewald | Jul 2010 | A1 |
| 20100168739 | Wu et al. | Jul 2010 | A1 |
| 20100174282 | Demarais et al. | Jul 2010 | A1 |
| 20100179424 | Warnking et al. | Jul 2010 | A1 |
| 20100189974 | Ochi et al. | Jul 2010 | A1 |
| 20100191112 | Demarais et al. | Jul 2010 | A1 |
| 20100198065 | Thapliyal et al. | Aug 2010 | A1 |
| 20100249859 | Dilorenzo | Sep 2010 | A1 |
| 20100291722 | Kim | Nov 2010 | A1 |
| 20110004184 | Proksch et al. | Jan 2011 | A1 |
| 20110060324 | Wu et al. | Mar 2011 | A1 |
| 20110087096 | Behar | Apr 2011 | A1 |
| 20110087097 | Behar | Apr 2011 | A1 |
| 20110104060 | Seward | May 2011 | A1 |
| 20110112400 | Emery | May 2011 | A1 |
| 20110118598 | Gertner | May 2011 | A1 |
| 20110137298 | Nguyen et al. | Jun 2011 | A1 |
| 20110172527 | Gertner | Jul 2011 | A1 |
| 20110178516 | Orszulak et al. | Jul 2011 | A1 |
| 20110200171 | Beetel et al. | Aug 2011 | A1 |
| 20110208096 | Demarais et al. | Aug 2011 | A1 |
| 20110257523 | Hastings | Oct 2011 | A1 |
| 20110257562 | Schaer | Oct 2011 | A1 |
| 20110257563 | Thapliyal et al. | Oct 2011 | A1 |
| 20110257564 | Demarais et al. | Oct 2011 | A1 |
| 20110257647 | Mayse | Oct 2011 | A1 |
| 20110301662 | Bar-Yoseph et al. | Dec 2011 | A1 |
| 20110319765 | Gertner et al. | Dec 2011 | A1 |
| 20120004656 | Jackson et al. | Jan 2012 | A1 |
| 20120065493 | Gertner | Mar 2012 | A1 |
| 20120065554 | Pikus | Mar 2012 | A1 |
| 20120078278 | Bales et al. | Mar 2012 | A1 |
| 20120095461 | Herscher et al. | Apr 2012 | A1 |
| 20120123243 | Hastings | May 2012 | A1 |
| 20120123303 | Sogard et al. | May 2012 | A1 |
| 20120143097 | Pike, Jr. | Jun 2012 | A1 |
| 20120165667 | Altmann et al. | Jun 2012 | A1 |
| 20120172723 | Gertner | Jul 2012 | A1 |
| 20120209118 | Warnking | Aug 2012 | A1 |
| 20120215106 | Sverdlik et al. | Aug 2012 | A1 |
| 20120232436 | Warnking | Sep 2012 | A1 |
| 20120238918 | Gertner | Sep 2012 | A1 |
| 20120238919 | Gertner | Sep 2012 | A1 |
| 20120265198 | Crow et al. | Oct 2012 | A1 |
| 20120316439 | Behar | Dec 2012 | A1 |
| 20130012844 | Demarais et al. | Jan 2013 | A1 |
| 20130090650 | Jenson et al. | Apr 2013 | A1 |
| 20130103064 | Arenson et al. | Apr 2013 | A1 |
| 20130110012 | Gertner | May 2013 | A1 |
| 20130131668 | Schaer | May 2013 | A1 |
| 20130138018 | Gertner | May 2013 | A1 |
| 20130158441 | Demarais et al. | Jun 2013 | A1 |
| 20130158442 | Demarais et al. | Jun 2013 | A1 |
| 20130165822 | Demarais et al. | Jun 2013 | A1 |
| 20130165924 | Mathur et al. | Jun 2013 | A1 |
| 20130197555 | Schaer | Aug 2013 | A1 |
| 20130204167 | Sverdlik et al. | Aug 2013 | A1 |
| 20130211396 | Sverdlik et al. | Aug 2013 | A1 |
| 20130218054 | Sverdlik et al. | Aug 2013 | A1 |
| 20130274658 | Steinke et al. | Oct 2013 | A1 |
| 20130282084 | Mathur et al. | Oct 2013 | A1 |
| 20130304047 | Grunewald et al. | Nov 2013 | A1 |
| 20130331739 | Gertner | Dec 2013 | A1 |
| 20140012133 | Sverdlik et al. | Jan 2014 | A1 |
| 20140018794 | Anderson et al. | Jan 2014 | A1 |
| 20140025069 | Willard | Jan 2014 | A1 |
| 20140039477 | Sverdlik et al. | Feb 2014 | A1 |
| 20140046313 | Pederson et al. | Feb 2014 | A1 |
| 20140067029 | Schauer et al. | Mar 2014 | A1 |
| 20140074083 | Horn et al. | Mar 2014 | A1 |
| 20140107482 | Warnking | Apr 2014 | A1 |
| 20140107639 | Zhang et al. | Apr 2014 | A1 |
| 20140163540 | Iyer et al. | Jun 2014 | A1 |
| 20140180196 | Stone et al. | Jun 2014 | A1 |
| 20140180197 | Sverdlik et al. | Jun 2014 | A1 |
| 20140194785 | Gertner | Jul 2014 | A1 |
| 20140200489 | Behar et al. | Jul 2014 | A1 |
| 20140214018 | Behar et al. | Jul 2014 | A1 |
| 20140249524 | Kocur | Sep 2014 | A1 |
| 20140272110 | Taylor et al. | Sep 2014 | A1 |
| 20140275924 | Min et al. | Sep 2014 | A1 |
| 20140276742 | Nabutovsky | Sep 2014 | A1 |
| 20140276752 | Wang et al. | Sep 2014 | A1 |
| 20140276755 | Cao et al. | Sep 2014 | A1 |
| 20140276789 | Dandler et al. | Sep 2014 | A1 |
| 20140277033 | Taylor | Sep 2014 | A1 |
| 20150025518 | Kobayashi | Jan 2015 | A1 |
| 20150105715 | Pikus | Apr 2015 | A1 |
| 20150111918 | Sobotka | Apr 2015 | A1 |
| 20150223877 | Behar et al. | Aug 2015 | A1 |
| 20150335919 | Behar et al. | Nov 2015 | A1 |
| 20160016016 | Taylor et al. | Jan 2016 | A1 |
| 20160175582 | Serna | Jun 2016 | A1 |
| 20160331459 | Townley | Nov 2016 | A1 |
| Number | Date | Country |
|---|---|---|
| 20 2005 022 060 | Nov 2012 | DE |
| 0 623 360 | Nov 1994 | EP |
| 0 659 387 | Jun 1995 | EP |
| 0 767 630 | Apr 1997 | EP |
| 0 774 276 | May 1997 | EP |
| 0 838 980 | Apr 1998 | EP |
| 1 042 990 | Oct 2000 | EP |
| 1 100 375 | May 2001 | EP |
| 1 384 445 | Jan 2004 | EP |
| 1 598 024 | Nov 2005 | EP |
| 1 647 305 | Apr 2006 | EP |
| 2 218 479 | Aug 2010 | EP |
| 2 359 764 | Aug 2011 | EP |
| 2 430 996 | Mar 2012 | EP |
| 2 457 614 | May 2012 | EP |
| 2 460 486 | Jun 2012 | EP |
| 2 495 012 | Sep 2012 | EP |
| 2 521 593 | Nov 2012 | EP |
| 2 561 903 | Feb 2013 | EP |
| 2 561 905 | Feb 2013 | EP |
| 2 626 022 | Aug 2013 | EP |
| 2 632 373 | Sep 2013 | EP |
| 2 662 041 | Nov 2013 | EP |
| 2 662 043 | Nov 2013 | EP |
| 2 037 166 | Jul 1980 | GB |
| 05-068684 | Mar 1993 | JP |
| 07-178173 | Jul 1995 | JP |
| 40-826437 | Oct 1996 | JP |
| 10-127678 | May 1998 | JP |
| 10-507229 | Jul 1998 | JP |
| 11-218100 | Aug 1999 | JP |
| 2000-054153 | Feb 2000 | JP |
| 2001-011126 | Apr 2001 | JP |
| 2001-111126 | Apr 2001 | JP |
| 2002-078809 | Mar 2002 | JP |
| 2006-161116 | Jun 2006 | JP |
| 2008-214669 | Sep 2008 | JP |
| 2011-219828 | Nov 2011 | JP |
| WO-9000420 | Jan 1990 | WO |
| WO-9207622 | May 1992 | WO |
| WO-9220291 | Nov 1992 | WO |
| WO-9405365 | Mar 1994 | WO |
| WO-9411057 | May 1994 | WO |
| WO-9519143 | Jul 1995 | WO |
| WO-9525472 | Sep 1995 | WO |
| WO-9600039 | Jan 1996 | WO |
| WO-9713463 | Apr 1997 | WO |
| WO-9736548 | Oct 1997 | WO |
| WO-9841178 | Sep 1998 | WO |
| WO-9842403 | Oct 1998 | WO |
| WO-9849957 | Nov 1998 | WO |
| WO-9852465 | Nov 1998 | WO |
| WO-9902096 | Jan 1999 | WO |
| WO-9935987 | Jul 1999 | WO |
| WO-9944519 | Sep 1999 | WO |
| WO-9952423 | Oct 1999 | WO |
| WO-9956812 | Nov 1999 | WO |
| WO-0016850 | Mar 2000 | WO |
| WO-0027292 | May 2000 | WO |
| WO-0041881 | Jul 2000 | WO |
| WO-0042934 | Jul 2000 | WO |
| WO-0051511 | Sep 2000 | WO |
| WO-0051683 | Sep 2000 | WO |
| WO-0056237 | Sep 2000 | WO |
| WO-0057495 | Sep 2000 | WO |
| WO-0067648 | Nov 2000 | WO |
| WO-0067656 | Nov 2000 | WO |
| WO-0067659 | Nov 2000 | WO |
| WO-0067830 | Nov 2000 | WO |
| WO-0067832 | Nov 2000 | WO |
| WO-0113357 | Feb 2001 | WO |
| WO-0122897 | Apr 2001 | WO |
| WO-0137925 | May 2001 | WO |
| WO-0170114 | Sep 2001 | WO |
| WO-0180723 | Nov 2001 | WO |
| WO-0182814 | Nov 2001 | WO |
| WO-0205868 | Jan 2002 | WO |
| WO-02083196 | Oct 2002 | WO |
| WO-02085192 | Oct 2002 | WO |
| WO-03003930 | Jan 2003 | WO |
| WO-03059437 | Jul 2003 | WO |
| WO-03099382 | Dec 2003 | WO |
| WO-2004023978 | Mar 2004 | WO |
| WO-2004091255 | Oct 2004 | WO |
| WO-2005009218 | Feb 2005 | WO |
| WO-2006041847 | Apr 2006 | WO |
| WO-2006041881 | Apr 2006 | WO |
| WO-2006060053 | Jun 2006 | WO |
| WO-2007124458 | Nov 2007 | WO |
| WO-2007135875 | Nov 2007 | WO |
| WO-2007146834 | Dec 2007 | WO |
| WO-2008003058 | Jan 2008 | WO |
| WO-2008036479 | Mar 2008 | WO |
| WO-2008052186 | May 2008 | WO |
| WO-2008061152 | May 2008 | WO |
| WO-2008151001 | Dec 2008 | WO |
| WO-2009149315 | Dec 2009 | WO |
| WO-2010033940 | Mar 2010 | WO |
| WO-2010067360 | Jun 2010 | WO |
| WO-2011046880 | Apr 2011 | WO |
| WO-2011053757 | May 2011 | WO |
| WO-2011082279 | Jul 2011 | WO |
| WO-2011088399 | Jul 2011 | WO |
| WO-2011094367 | Aug 2011 | WO |
| WO-2011139589 | Nov 2011 | WO |
| WO-2012112165 | Aug 2012 | WO |
| Entry |
|---|
| Arruda, M.S., et al. “Development and validation of an ECG algorithm for identifying accessory pathway ablation site in Wolff-Parkinson-White syndrome.” J Cardiovasc Electrophysiol, 9:2-12 (1998). |
| Avitall, B., et al. “The creation of linear continuous lesions in the atria with an expandable loop catheter.” J Am Coll Cardiol, 33,4:972-974 (1999). |
| Bartlett, T.G., et al. “Current management of the Wolff-Parkinson-White syndrome.” J Card Surg. 8:503-515(1993). |
| Benito, F., et al. “Radio frequency catheter ablation of accessory pathways in infants,” Heart, 78:160-162 (1997). |
| Blumenfeld, J.D., et al. “β-Adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.” AJH, 12:451-459 (1999). |
| Callans, D. J. “Narrowing of the superior vena cava—right atrium junction during radiofrequency catheter ablation for inappropriate sinus tachycardia: Analysis with intracardiac echocardiography.” JACC, 33:1667-1670 (1999). |
| Cao, H., et al. “Flow effect on lesion formation in RF cardiac catheter ablation.” IEEE T Bio-Med Eng, 48:425-433 (2001). |
| Chen, S.-A., et al. “Complications of diagnostic electrophysiologic studies and radiofrequency catheter ablation in patients with tachyarrhythmias: An eight-year survey of 3,966 consecutive procedures in a tertiary referral center.” Am J Cardiol, 77:41-46 (1996). |
| Chen, Shih-Ann, M.D., “Initiation of Atrial Fibrillation by Ectopic Beats Originating From the Pulmonary Veins,” Circulation 100(18): 1879-86, 1999. |
| Chinitz, et al., “Mapping Reentry Around Atriotomy Scars Using Double Potentials,” Pacing and Clinical Electrophysiology, Cardiostim 96 Proceedings, Part II, vol. 19:1978-1983 (1996). |
| Cioni, R., et al. “Renal artery stenting in patients with a solitary functioning kidney.” Cardiovasc Intervent Radiol, 24:372-377 (2001). |
| Cosby, R.L., et al. “The role of the sympathetic nervous system and vasopressin in the pathogenesis of the abnormal sodium and water.” Nefrologia, V, 4:271-277 (1985). |
| Cosio, Francisco G., “Atrial Flutter Mapping and Ablation II,” Pacing & Clin. Electrophysiol. 19(6):965-75, 1996. |
| Cox, J.L. “The status of surgery for cardiac arrhythmias.” Circulation, 71 :413-417 (1985). |
| Cox, J.L. et al. “Five-year experience with the Maze procedure for atrial fibrillation.” Ann Thorac Surg, 56:814-824 (1993). |
| Cruickshank, J.M. “Beta-blockers continue to surprise us.” Eur Heart J, 21:354-364 (2000). |
| Curtis, J.J., et al. “Surgical therapy for persistent hypertension after renal transplantation,” Transplantation, 31:125-128 (1981). |
| Demazumder, D., et al. “Comparison of irrigated electrode designs for radiofrequency ablation of myocardium.” J Interv Card Electr, 5:391-400 (2001). |
| DiBona, G.F. “Neural control of the kidney: Functionally specific renal sympathetic nerve fibers.” Am J Physiol Regulatory Integrative Comp Physiol, 279:R1517-R1524 (2000). |
| DiBona, G.F. “Sympathetic nervous system and kidney in hypertension,” Nephrol and Hypertension, 11:197-200 (2002). |
| DiBona, G.F., et al. “Neural control of renal function,” Physiol Rev, 77:75-197 (1997). |
| DiBona, G.F., et al. “Renal hemodynamic effects of activation of specific renal sympathetic nerve fibergroups.” Am J Physiol Regul Integr Comp Physiol, 276:R539-R539 (1999). |
| Diederich C.J. et al. “Transurethral Ultrasound Array for Prostate Thermal Therapy: Initial Studies”, IEEE Transactions on Ultrasonic, Ferroelectronics And Frequency Control IEEEE USA, vol. 43 No. 6 Nov. 1996 pp. 1011-1022. |
| Doggrell, S.A., et al. “Rat models of hypertension, cardiac hypertrophy and failure.” Cardiovasc Res, 39:89-105 (1998). |
| Dong Q., et al. “Diagnosis of renal vascular disease with MR angiography.” RadioGraphies, 19:1535-1554 (1999). |
| Dubuc, M., et al. “Feasibility of cardiac cryoablation using a transvenous steerable electrode catheter,” J Interv Cardiac Electrophysiol, 2:285-292 (1998). |
| Extended European Search Report, Application No. EP 10 72 9496, dated Jul. 25, 2012. |
| Feld, Gregory K., “Radiofrequency Catheter Ablation for the Treatment of Human Type I Atrial Flutter,” Circulation, 86(3):1233-1240 (1992). |
| Gallagher, John J., “Wolff-Parkinson-White Syndrome: Surgery to Radiofrequency Catheter Ablation,” 1997. |
| Gilard, M., et al. “Angiographic anatomy of the coronary sinus and its tributaries.” PACE, 21:2280-2284 (1998). |
| Gorisch, W., et al. “Heat-induced contraction of blood vessels.” Lasers Surg Med, 2:1-13 (1982). |
| Haines, D.E. et al. “Tissue heating during radiofrequency catheter ablation; A thermodynamic model and observations in isolated perfused and superfused canine right ventricular free wall.” PACE, 12:962-976 (1989). |
| Haissaguerre, et al., “Radiofrequency Catheter Ablation in Unusual Mechanisms of Atrial Fibrillation,” Journal of Cardiovascular Electrophysiology, 5(9)743-1751 (1994). |
| Haissaguerre, et al., “Right and Left Atrial Radiofrequency Catheter Therapy of Paroxysmal Atrial Fibrillation,” Journal of Cardiovascular Electrophysiology, 7(12):1133-1144 (1996). |
| Haissaguerre, Michel, “Electrophysiological End Point for Catheter Ablation of Atrial Fibrillation Initiated From Multiple Venous Foci,” Circulation, 101:1409-1417 (2000). |
| Haissaguerre, Michel, M.D., “Predominant Origin of Atrial Panarrhythmic Triggers in the Pulmonary Veins: A Distinct Electrophysiologic Entity,” 1997. |
| Haissaguerre, Michel, M.D., et al., “Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins,”The New England Journal of Medicine, 339(10):659-666 (1998). |
| Han, Y-M., et al. “Renal artery embolization with diluted hot contrast medium: An experimental study,” J Vase Interv Radiol, 12:862-868 (2001). |
| Hatala, Robert, “Radiofrequency Catheter Ablation of Left Atrial Tachycardia Originating Within the Pulmonary Vein in a Patient with Dextrocardia,” Pacing and Clinical Electrophysiology, 19(6):999-1002 (1996). |
| Hindricks, G. “The Multicentre European Radiofrequency Survey (MERFS): Complications of radiofrequency catheter ablation of arrhythmias.” Eur Heart J, 14:1644-1653 (1993). |
| Ho, S.Y., et al. “Architecture of the pulmonary veins: Relevance to the radiofrequency ablation.” Heart 86:265-270 (2001). |
| Hocini, et al., “Concealed Left Pulmonary Vein Potentials Unmasked by Left Atrial Stimulation,” Pacing and Clinical Electrophysiology, 23(11):1828-1831, part 2 (2000). |
| Hocini, et al., “Multiple Sources initiating Atrial Fibrillation from a Single Pulmonary Vein Identified by a Circumferential Catheter,” Pacing and Clinical Electrophysiology, 23(11):1828-1831, Part 2 (2000). |
| Hsieh, et al., “Double Multielectrode Mapping Catheters Facilitate Radiofrequency Catheter Ablation of Focal Atrial Fibrillation Originating from Pulmonary Veins,” Journal of Cardiovascular Electrophysiology, 10(2):136-144 (1999). |
| Huang et al., “Renal denervation prevents and reverses hyperinsulinemia-induced hypertension in rats,” Hypertension 32, pp. 249-254 (1998). |
| Huang, S.K.S., et al. “Radiofrequency catheter ablation of cardiac arrhythmias: Basic concepts and clinical applications.” 2nd ed. Armonk, NY: Futura Publishing Co. (2000). |
| Igawa, et al., “The Anatomical Features of the Junction between the Left Atrium and the Pulmonary Veins: The Relevance with Atrial Arrhythmia”, Circulation, Journal of the American Heart Association, Abstracts from the 72nd Scientific Sessions, 100(18):l-285 (1999). |
| International Search Report for PCT/US2010//020333 dated Feb. 25, 2010. |
| International Search Report, Application No. PCT/US01/22237 dated Sep. 19, 2002. |
| International Search Report, Application No. PCT/US04/05197 dated Apr. 12, 2005. |
| International Search Report, Application No. PCT/US07/11346 dated Jan. 9, 2008. |
| International Search Report, Application No. PCT/US2001/022221 dated Jan. 3, 2002. |
| Jackman, W.M., et al. “Treatment of supraventricular tachycardia due to atrioventricular nodal reentry by radiofrequency catheter ablation of slow-pathway conduction.” N England J Med, 327, 5:313-318 (Jul. 30, 1992). |
| Jain, M.K., et al. “A three-dimensional finite element model of radiofrequency ablation with blood flow and its experimental validation.” Ann Biomed Eng, 28:1075-1084 (2000). |
| Jais, Pierre, M.D., “A Focal Source of Atrial Fibrillation Treated by Discrete Radiofrequency Ablation,” Circulation, 95(3):572-576 (1996). |
| Janssen, B.J.A., et al. “Renal nerves in hypertension.” Miner Electrolyte Metab, 15:74-82 (1989). |
| Kapural, L., et al. “Radiofrequency ablation for chronic pain control.” Curr Pain Headache Rep, 5:517-525 (2001). |
| Kay, et al., “Radiofrequency Ablation for Treatment of Primary Atrial Tachycardia,” Journal of the American College of Cardiology, 21 (4):901-909 (1993). |
| Koepke, J.P., et al. “The physiology teacher: Functions of the renal nerves.” The Physiologist, 28, 1:47-52 (1985). |
| Kompanowska-Jezierska, et al. “Early effects of renal denervation in the anaesthetised rat: Natriuresis and increased cortical blood flow,” J Physiol, 531.2:527-534 (2001). |
| Krimholtz et al., “New Equivalent Circuits for Elementary Piezoelectric Transducers,” Electronics Lettres, vol. 6, No. 13, pp. 398-399, Jun. 25, 1970. |
| Kumagai, et al., “Treatment of Mixed Atrial Fibrillation and Typical Atrial Flutter by Hybrid Catheter Ablation,” Pacing and Clinical Electrophysiology, 23(11):1839-1842, Part 2 (2000). |
| Labonte, S. “Numerical model for radio-frequency ablation of the endocardium and its experimental validation.” IEEE T Bio-med Eng, 41,2:108-115 (1994). |
| Lee, S.-J., et al. “Ultrasonic energy in endoscopic surgery,” Yonsei Med J, 40:545-549 (1999). |
| Leertouwer, Tic., et al. “In-vitro validation, with histology, of intravascular ultrasound in renal arteries.” J Hypertens, 17:271-277 (1999). |
| Lesh, M.D., “An Anatomic Approach to Prevention of Atrial Fibrillation: Pulmonary Vein Isolation with Through-the-Balloon Ultrasound Ablation (TTB-US),” Thorac. Cardiovasc. Surg. 47 (1999) (Suppl.) 347-51. |
| Lesh, Michael D., M.D., “Radiofrequency Catheter Ablation of Atrial Arrhythmias,” Circulation, 89(3):1074-1089 (1994). |
| Levin, H.R., et al. “Modulation of renal nerve to treat CHF.” U.S. Appl. No. 60/370,190, filed 2002. |
| Liem, L. Bing, “In Vitro and In Vivo Results of Transcatheter Microwave Ablation Using Forward-Firing Tip Antenna Design,” Pacing and Clinical Electrophysiology, Cardiostim '96 Proceedings, 19(11), Part 2 pp. 2004-2008 (1996). |
| Lin, Wei-Shiang, M.D., “Pulmonary Vein Morphology in Patients with Paroxysmal Atrial Fibrillation Initiated by Ectopic Beats Originating From the Pulmonary Veins,” Circulation 101 (11): 1274-81, 2000. |
| Lowe, J.E. “Surgical treatment of the Wolff-Parkinson-White syndrome and other supraventricular tachyarrhythmias.” J Card Surg, 1 :117-134 (1986). |
| Lundin, S et al. “Renal sympathetic activity in spontaneously hypertensive rats and normotensive controls, as studied by three different methods.” Acta Physiol Scan, 120,2:265-272 (1984). |
| Lustgarten, D.L., et al. “Cryothermal ablation: Mechanism of tissue injury and current experience in the treatment of tachyarrhythmias,” Progr Cardiovasc Dis, 41:481-498 (1999). |
| Mallavarapu, Christopher, “Radiofrequency Catheter Ablation of Atrial Tachycardia with Unusual Left Atrial Sites of Origin,” Pacing and Clinical Electrophysiology, vol. 19(6), pp. 988-992 (1996). |
| McRury, I.D., et al. “Nonuniform heating during radiofrequency catheter ablation with long electrodes.” Circulation, 96:4057-4064 (1997). |
| Mehdirad, A., et al. “Temperature controlled RF ablation in canine ventricle and coronary sinus using 7 Fr or 5 Fr ablation electrodes.” PACE, 21:310-321 (1998). |
| Miller, B.F., and Keane, C.B. “Miller-Keane Encyclopedia & Dictionary of Medicine, Nursing, & Allied Health.” Philadelphia: Saunders (1997) (“ablation”). |
| Misaki, T., et al. “Surgical treatment of patients with Wolff-ParkinsonWhite syndrome and associated Ebstein's anomaly.” J Thoracic Cardiovase Surg, 110: 1702-1707 (1995). |
| Moak, J.P., et al. “Case report: Pulmonary vein stenosis following RF ablation of paroxysmal atrial fibrillation: Successful treatment with balloon dilation.” J Interv Card Electrophys, 4:621-631 (2000). |
| Montenero, Sandro, Annibale, “Electrograms for Identification of the Atrial Ablation Site During Catheter Ablation of Accessory Pathways,” Pacing and Clinical Electrophysiology, vol. 19(6), pp. 905-912 (1996). |
| Morrissey, D.M., “Sympathectomy in the treatment of hypertension.” Lancet, CCLXIV:403-408 (1953). |
| Moubarak, Jean B., “Pulmonary Veins-Left Atrial Junction: Anatomic and Histological Study,” Pacing & Clin. Electrophys. 23(11 pt. 2):1836-8, 2000. |
| Nakagawa, A., et al. “Selective ablation of porcine and rabbit liver tissue using radiofrequency: Preclinical study.” EurSurg Res, 31:371-379 (1999). |
| Nakagawa, H., et al. “Comparison of in vivo tissue temperature profile and lesion geometry for radiofrequency ablation with a saline-irrigated electrode versus temperature control in a canine thigh muscle preparation.” Circulation, 91 :2264-2273 (1995). |
| Nakagawa, H., et al. “Inverse relationship between electrode size and lesion size during radiofrequency ablation with active electrode cooling.” Circulation, 98:458-465 (1998). |
| Neutel, J. M. “Hypertension and its management: A problem in need of new treatment strategies.” JRAAS, l:S 1 O-S 13 (2000). |
| Nozawa, T., et al. “Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats.” Heart Vessels, 16:51-56 (2002). |
| O'Connor, B.K., et al. “Radiofrequency ablation of a posteroseptal accessory pathway via the middle cardiac vein in a six-year-old child.” PACE, 20:2504-2507 (1997). |
| Oliveira et al., “Renal Denervation Normalized Pressure and Baroreceptor Reflex in High Renin Hypertension in Conscious Rats,” Hypertension Suppl. II vol. 19 No. 2 pp. 17-21 (1992). |
| Oral, H., et al. “Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation.” Circulation, 105:1077-1081 (2002). |
| Page, I., et al. “The effect of renal denervation in the level of arterial blood pressure and renal function in essential hypertension.” J Clin Invest, XIV:27-30 (1935). |
| Panescu, D., et al. “Radiofrequency multielectrode catheter ablation in the atrium.” Phys Med Biol, 44:899-915(1999). |
| Partial European Search Report, Application No. 10 01 0582, dated Sep. 20, 2011. |
| Partial Supplementary European Search Report, Application No. EP 01 95 2750, dated Aug. 15, 2005. |
| Pavin, D., et al. “Permanent left atrial tachycardia: Radiofrequency catheter ablation through the coronary sinus.” J Cardiovasc Electrophysiol, 12:395-398 (2002). |
| Peet, M., “Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy,” Am. J. Surgery, pp. 48-68 (1948).g. |
| Petersen, H. H., et al. “Lesion dimensions during temperature controlled radiofrequency catheter ablation of left ventricular porcine myocardium: Impact of ablation site, electrode size, and convective cooling.” Circulation, 99:319-325 (1999). |
| Pohl, M.A. “Renovascular hypertension and ischemic nephropathy” A chapter in a book edited by Sehrier, R.W. “Atlas of diseases of the kidney: Hypertension and the kidney.” Blackwell Science (1999). |
| Prager, Nelson, A., “Long Term Effectiveness of Surgical Treatment of Ectopic Atrial Tachycardia,” Journal of the American College of Cardiology, vol. 22(1):85-92 (1993). |
| Pugsley, M.K., et al. “The vascular system An overview of structure and function.” J Pharmacol Toxical Methods, 44:333-340 (2000). |
| Rappaport et al. “Wide-Aperture Microwave Catheter-Based Cardiac Ablation”, Proceedings of the First Joint BMES/EMBS Conference, Oct. 13-16, 1999, p. 314. |
| Response to Written Opinion under Article 34 for PCT/US2010/020333, filed Nov. 8, 2010, 13 pages. |
| Reuter, David, M.D., et al., “Future Directions of Electrotherapy for Atrial Fibrillation,” Journal of Cardiovascular Electrophysiology, 9(8):S202-S210 (1998). |
| Robbins, Ivan, M.D., “Pulmonary Vein Stenosis After Catheter Ablation of Atrial Fibrillation,” Circulation, 98:1769-1775 (1998). |
| Sanderson, J.E., et al. “Effect of B-blockage on baroreceptor and autonomic function in heart failure.” Clin Sei, 69:137-146 (1999). |
| Schauerte, P., et al. “Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation,” Circulation, 102:2774-2780 (2000). |
| Scheinman, M. M., et al. “The 1998 NASPE prospective catheter ablation registry.” PACE, 23:1020-1028 (2000). |
| Scheinman, Melvin M., “NASPE Survey on Catheter Ablation,” 1995. |
| Smithwick et al., “Splanchnicetomy for Essential Hypertension,” J. Am. Med. Assn. 152:16, pp. 1501-1504 (1953). |
| Solis-Herruzo et al., “Effects Lumbar Sympathetic Block on Kidney Function in Cirrhotic Patients with Hepatorneal Syndrome,” J. Hepatol. 5, pp. 167-173 (1987). |
| Stella, A., et al. “Effects of reversible renal denervation on hemodynamic and excretory functions of the ipsilateral and contralateral kidney in the cat,” J Hypertension, 4:181-188 (1986). |
| Stellbrink, C., et al. “Transcoronary venous radiofrequency catheter ablation of ventricular tachycardia.” J Cardiovasc Electropysiol 8:916-921 (1997). |
| Supplementary European Search Report, Application No. EP 01 952 746.4, dated Feb. 24, 2005. |
| Supplementary European Search Report, Application No. EP 01 952 750.6, dated Dec. 6, 2005. |
| Supplementary European Search Report, Application No. EP 07 77 6968, dated Jan. 25, 2010. |
| Swain, et al., An endoscopically deliverable tissue-transfixing device for securing biosensors in the gastrointestinal tract, Gastrointestinal Endoscopy. 1994, 40:AB35. |
| Swartz, John F., “A Catheter-based Curative Approach to Atrial Fibrillation in Humans,” Circulation, Abstracts from the 67th Scientific Sessions, Clinical Cardiology: Radio Frequency Ablation of Atrial Arrhythmias, 90(4), part 2, I-335 (1994). |
| Swartz, John F., M.D., “Radiofrequency Endocardial Catheter Ablation of Accessory Atrioventricular Pathway Atrial Insertion Sites,” Circulation, 87:487-499 (1993). |
| Takahashi, H., et al. “Retardation of the development of hypertension in DOCA-salt rats by renal denervation.” Jpn Circ J, 48:567-574 (1984). |
| Tanaka et al., “A new radiofrequency thermal balloon catheter for pulmonary vein isolation,” Journal of the American College of Cardiology 38(7): 2079-86, Dec. 2001. |
| Tracy, Cynthia M., “Radiofrequency Catheter Ablation of Ectopic Atrial Tachycardia Using Paced Activation Sequence Mapping,” J. of the Amer. College of Cardiol. 21 (4):910-7, 1993. |
| Tungjitkusolmun, S. “Ablation.” A chapter in a book edited by Webster, J. G., “Minimally invasive medical technology.” Bristol UK: IOP Publishing, 219 (2001). |
| Uchida, F., et al. “Effect of radio frequency catheter ablation on parasympathetic denervation: A comparison of three different ablation sites,” PACE, 21:2517-2521 (1998). |
| Uflacker, R., “Atlas of vascular anatomy: An angiographic approach.” Baltimore: Williams & Wilkins, 424 (1997). |
| Valente, J. F. “Laparoscopic renal denervation for intractable ADPKD-related pain,” Nephrol Dial Transplant, 16:160 (2001). |
| Van Hare, G. F., et al. “Percutaneous radiofrequency catheter ablation for supraventricular arrhythmias in children.” JACC, 17:1613-1620 (1991). |
| Van Hare, George F., “Radiofrequency Catheter Ablation of Supraventricular Arrhythmias in Patients With Congenital Heart Disease: Results and Technical Considerations,” J. of the Amer. College of Cardiol. 22(3):883-90, 1993. |
| Volkmer, Marius, M.D., “Focal Atrial Tachycardia from Deep Inside the Pulmonary Veins,” PACE vol. 20:533, p. 1183 (1997). |
| Vujaskovie, Z., et al. “Effects of intraoperative hyperthermia on canine sciatic nerve: Histopathology and morphometric studies.” Int. J. Hyperthermia, 10,6:845-855 (1994). |
| Walsh, Edward P., M.D., “Transcatheter Ablation of Ectopic Atrial Tachycardia in Young Patients Using Radiofrequency Current,” Circulation, 86(4):1138-1146 (1992). |
| Weinstock, M., et al. “Renal denervation prevents sodium retention and hypertension in salt-sensitive rabbits with genetic baroreflex impairment,” Clinical Science, 90:287-293 (1996). |
| Weir, M. R., et al. “The renin-angiotensin-aldosterone system: A specific target for hypertension management.” Am J Hypertens, 12:205S-213S (1999). |
| Written Opinion of the International Searching Authority for PCT/US2010/020333, dated Feb. 25, 2010, 7 pages. |
| Yamamoto, T., et al. “Blood velocity profiles in the human renal artery by Doppler ultrasound and their relationship to atherosclerosis.” Arterisocl Throm Vas, 16:172-177 (1996). |
| Zhang et al., “The development of a RF electrical pole catheter for heart ablation,” China Academic Journal Electronic Publishing House 23(5): 279-80, Sep. 1999 (With English Abstract). |
| Zipes, Douglas P., M.D., “Catheter Ablation of Arrhythmias,” 1994. |
| Bhatt, et al., A Controlled Trial of Renal Denervation for Resistant Hypertension, N. Engl. J. Med., 370:1393-1401 (2014). |
| Bunch, Jared, et al., Mechanisms of Phrenic Nerve Injury During Radiofrequency Ablation at the Pulmonary Vein Orifice, Journal of Cardiovascular Electrophysiology, 16(12): 1318-1325 (2005). |
| Campese, et al., Renal afferent denervation prevents hypertension in rats with chronic renal failure, Hypertension, 25:878-882 (1995). |
| Dibona, Renal nerves in compensatory renal response to contralateral renal denervation, Renal Physiology, 238 (1):F26-F30 (1980). |
| Extended EP Search Report dated Dec. 5, 2016 in EP Patent Application Serial No. 16183988.1. |
| Extended European Search Report dated Feb. 15, 2016 in EP Patent Application Serial No. 15182333.3. |
| Extended European Search Report dated Feb. 17, 2016 in EP Patent Application Serial No. 14775754.6. |
| International Search Report & Written Opinion dated Jul. 9, 2014 in Int'l PCT Patent Appl. Serial No. PCT/US2014/22804. |
| International Search Report & Written Opinion dated Nov. 29, 2011 in Int'l PCT Patent Appl. Serial No. PCT/US2011/025543. |
| International Search Report dated Feb. 9, 2014 in Int'l PCT Patent Appl. Serial No. PCT/US2014/022796. |
| International Search Report dated Jul. 9, 2014 in Int'l PCT Patent Appl. Serial No. PCT/US2014/22804. |
| Medtronic Announces U.S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint While Meeting Primary Safety Endpoint, Medtronic Press Release, Jan. 9, 2014. |
| Oliveira, et a., Renal Denervation Normalizes Pressure and Baroreceptor Reflex in High Renin Hypertension in Conscious Rats, Hypertension 19:17-21 (1992). |
| OnlineMathLearning.com, Volume Formula, “Volume of a Hollow Cylinder”, Oct. 24, 2008. |
| Smithwick, R.H., Surgery in hypertension, Lancet, 2:65 (1948). |
| Smithwick, R.H., Surgical treatment of hypertension, Am. J. Med. 4:744-759 (1948). |
| Wang, S., et al., Effects of Low Intensity Ultrasound on the Conduction Property of Neural Tissues, IEEE International Ultrasonics, Ferroelectrics, and Frequency Control, Joint 50th Anniversary Conference, 2004. |
| Written Opinion dated Jul. 9, 2014 in Int'l PCT Patent Appl. Serial No. PCT/US2014/22804. |
| www.dictionary.com/browse/degrease, retrieved Jun. 7, 2016. |
| Number | Date | Country | |
|---|---|---|---|
| 20180361117 A1 | Dec 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61256429 | Oct 2009 | US | |
| 61292618 | Jan 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13826645 | Mar 2013 | US |
| Child | 16055014 | US | |
| Parent | 13503109 | US | |
| Child | 13826645 | US |
